Cargando…
Human first-trimester chorionic villi have a myogenic potential
First-trimester chorionic-villi-derived cells (FTCVs) are the earliest fetal material that can be obtained for prenatal diagnosis of fetal disorders such as Duchenne muscular dystrophy (DMD). DMD is a devastating X-linked disorder characterized by the absence of dystrophin at the sarcolemma of muscl...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316778/ https://www.ncbi.nlm.nih.gov/pubmed/22370594 http://dx.doi.org/10.1007/s00441-012-1340-9 |
_version_ | 1782228465892720640 |
---|---|
author | Arakawa, Reiko Aoki, Ryoko Arakawa, Masayuki Saito, Kayoko |
author_facet | Arakawa, Reiko Aoki, Ryoko Arakawa, Masayuki Saito, Kayoko |
author_sort | Arakawa, Reiko |
collection | PubMed |
description | First-trimester chorionic-villi-derived cells (FTCVs) are the earliest fetal material that can be obtained for prenatal diagnosis of fetal disorders such as Duchenne muscular dystrophy (DMD). DMD is a devastating X-linked disorder characterized by the absence of dystrophin at the sarcolemma of muscle fibers. Currently, a limited number of treatment options are available for DMD, although cell therapy is a promising treatment strategy for muscle degeneration in DMD patients. A novel candidate source of cells for this approach is FTCVs taken between the 9th and 11th weeks of gestation. FTCVs might have a higher undifferentiated potential than any other tissue-derived cells because they are the earliest fetal material. We examined the expression of mesenchymal stem cell and pluripotent stem cell markers in FTCVs, in addition to their myogenic potential. FTCVs expressed mesenchymal stem cell markers and Nanog and Sox2 transcription factors as pluripotent stem cell markers. These cells efficiently differentiated into myotubes after myogenic induction, at which point Nanog and Sox2 were down-regulated, whereas MyoD, myogenin, desmin and dystrophin were up-regulated. To our knowledge, this is the first demonstration that FTCVs can be efficiently directed to differentiate in vitro into skeletal muscle cells that express dystrophin as the last stage marker of myogenic differentiation. The myogenic potential of FTCVs reveals their promise for use in cell therapy for DMD, for which no effective treatment presently exists. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00441-012-1340-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3316778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-33167782012-04-05 Human first-trimester chorionic villi have a myogenic potential Arakawa, Reiko Aoki, Ryoko Arakawa, Masayuki Saito, Kayoko Cell Tissue Res Regular Article First-trimester chorionic-villi-derived cells (FTCVs) are the earliest fetal material that can be obtained for prenatal diagnosis of fetal disorders such as Duchenne muscular dystrophy (DMD). DMD is a devastating X-linked disorder characterized by the absence of dystrophin at the sarcolemma of muscle fibers. Currently, a limited number of treatment options are available for DMD, although cell therapy is a promising treatment strategy for muscle degeneration in DMD patients. A novel candidate source of cells for this approach is FTCVs taken between the 9th and 11th weeks of gestation. FTCVs might have a higher undifferentiated potential than any other tissue-derived cells because they are the earliest fetal material. We examined the expression of mesenchymal stem cell and pluripotent stem cell markers in FTCVs, in addition to their myogenic potential. FTCVs expressed mesenchymal stem cell markers and Nanog and Sox2 transcription factors as pluripotent stem cell markers. These cells efficiently differentiated into myotubes after myogenic induction, at which point Nanog and Sox2 were down-regulated, whereas MyoD, myogenin, desmin and dystrophin were up-regulated. To our knowledge, this is the first demonstration that FTCVs can be efficiently directed to differentiate in vitro into skeletal muscle cells that express dystrophin as the last stage marker of myogenic differentiation. The myogenic potential of FTCVs reveals their promise for use in cell therapy for DMD, for which no effective treatment presently exists. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00441-012-1340-9) contains supplementary material, which is available to authorized users. Springer-Verlag 2012-02-28 2012 /pmc/articles/PMC3316778/ /pubmed/22370594 http://dx.doi.org/10.1007/s00441-012-1340-9 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License, which permits any use, distribution and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Regular Article Arakawa, Reiko Aoki, Ryoko Arakawa, Masayuki Saito, Kayoko Human first-trimester chorionic villi have a myogenic potential |
title | Human first-trimester chorionic villi have a myogenic potential |
title_full | Human first-trimester chorionic villi have a myogenic potential |
title_fullStr | Human first-trimester chorionic villi have a myogenic potential |
title_full_unstemmed | Human first-trimester chorionic villi have a myogenic potential |
title_short | Human first-trimester chorionic villi have a myogenic potential |
title_sort | human first-trimester chorionic villi have a myogenic potential |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316778/ https://www.ncbi.nlm.nih.gov/pubmed/22370594 http://dx.doi.org/10.1007/s00441-012-1340-9 |
work_keys_str_mv | AT arakawareiko humanfirsttrimesterchorionicvillihaveamyogenicpotential AT aokiryoko humanfirsttrimesterchorionicvillihaveamyogenicpotential AT arakawamasayuki humanfirsttrimesterchorionicvillihaveamyogenicpotential AT saitokayoko humanfirsttrimesterchorionicvillihaveamyogenicpotential |